文献速递骨显像与常规 SPECT肿瘤 PET/CT

骨扫描与PSMA PET初始分期相比是否过度分期疾病?一项采用盲法独立阅片者的国际多中心回顾性研究

Do Bone Scans Overstage Disease Compared with PSMA PET at Initial Staging? An International Multicenter Retrospective Study with Masked Independent Readers.
PubMed 文献 · J Nucl Med · 2023-08-17

该国际多中心回顾性诊断研究以PSMA PET为参考标准,评估骨扫描检出骨转移的能力,纳入167例在前列腺癌不同疾病阶段接受骨扫描与PSMA PET检查(间隔100天内)的患者,由3名盲法阅片者独立判读。在初始分期患者中,骨扫描阳性预测值仅0.43,57%的阳性骨扫描为假阳性;骨扫描骨病阅片者间一致性为中等(Fleiss κ=0.51),PSMA PET参考标准为高度一致(Fleiss κ=0.80)。

要点

  • 初始分期患者中骨扫描阳性预测值为0.43(95%CI 0.26-0.63),57%的阳性骨扫描为假阳性。
  • 全部患者骨扫描阳性预测值0.73、阴性预测值0.82、特异度0.82。
  • 骨扫描骨病阅片者间一致性中等(Fleiss κ=0.51),PSMA PET为高度一致(Fleiss κ=0.80)。

核心结论

  • 在该多中心回顾性研究中,初始分期患者骨扫描阳性预测值低,57%的阳性骨扫描为假阳性。
  • 这提示相当一部分被骨扫描判为低体积转移的患者实际为局限性疾病,在将STAMPEDE M1放疗试验等临床试验数据应用于以PSMA PET分期的患者时这一点至关重要。

研究设计与样本

  • 国际多中心回顾性诊断研究,纳入167例前列腺癌患者,均在100天内完成骨扫描与PSMA PET检查。
  • 每项检查由3名盲法阅片者判读,以PSMA PET结果为参考标准。
  • 终点为骨扫描的阳性预测值、阴性预测值和特异度,并评估阅片者间可重复性、阳性率、PSMA PET摄取及病灶数目。
  • 167例中初始分期77例,生化复发及去势敏感前列腺癌60例,去势抵抗前列腺癌30例。

主要发现

  • 全部患者骨扫描阳性预测值为0.73(95%CI 0.61-0.82),阴性预测值为0.82(95%CI 0.74-0.88),特异度为0.82(95%CI 0.74-0.88)。
  • 初始分期患者骨扫描阳性预测值为0.43(95%CI 0.26-0.63),阴性预测值为0.94(95%CI 0.85-0.98),特异度为0.80(95%CI 0.68-0.88)。
  • 骨病阅片者间一致性骨扫描为中等(Fleiss κ=0.51),PSMA PET参考标准为高度一致(Fleiss κ=0.80)。

关键数值与推荐

  • 骨扫描阳性预测值:全部患者0.73(95%CI 0.61-0.82),初始分期患者0.43(95%CI 0.26-0.63)。
  • 骨扫描阴性预测值:全部患者0.82(95%CI 0.74-0.88),初始分期患者0.94(95%CI 0.85-0.98)。
  • 骨扫描特异度:全部患者0.82(95%CI 0.74-0.88),初始分期患者0.80(95%CI 0.68-0.88)。
  • 初始分期患者中57%的阳性骨扫描为假阳性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Prostate-specific membrane antigen (PSMA) PET has a higher accuracy than CT and bone scans to stage patients with prostate cancer. We do not understand how to apply clinical trial data based on conventional imaging to patients staged using PSMA PET. Therefore, we aimed to evaluate the ability of bone scans to detect osseous metastases using PSMA PET as a reference standard. Methods: In this multicenter retrospective diagnostic study, 167 patients with prostate cancer, who were imaged with bone scans and PSMA PET performed within 100 d, were included for analysis. Each study was interpreted by 3 masked readers, and the results of the PSMA PET were used as the reference standard. Endpoints were positive predictive value (PPV), negative predictive value (NPV), and specificity for bone scans. Additionally, interreader reproducibility, positivity rate, uptake on PSMA PET, and the number of lesions were evaluated. Results: In total, 167 patients were included, with 77 at initial staging, 60 in the biochemical recurrence and castration-sensitive prostate cancer setting, and 30 in the castration-resistant prostate cancer setting. In all patients, the PPV, NPV, and specificity for bone scans were 0.73 (95% CI, 0.61-0.82), 0.82 (95% CI, 0.74-0.88), and 0.82 (95% CI, 0.74-0.88), respectively. In patients at initial staging, the PPV, NPV, and specificity for bone scans were 0.43 (95% CI, 0.26-0.63), 0.94 (95% CI, 0.85-0.98), and 0.80 (95% CI, 0.68-0.88), respectively. Interreader agreement for bone disease was moderate for bone scans (Fleiss κ, 0.51) and substantial for the PSMA PET reference standard (Fleiss κ, 0.80). Conclusion: In this multicenter retrospective study, the PPV of bone scans was low in patients at initial staging, with 57% of positive bone scans being false positives. This suggests that a large proportion of patients considered low-volume metastatic by the bone scan actually had localized disease, which is critical when applying clinical data from trials such as the STAMPEDE M1 radiation therapy trial to patients being staged with PSMA PET.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Hope TA, Benz M, Jiang F, et al. Do Bone Scans Overstage Disease Compared with PSMA PET at Initial Staging? An International Multicenter Retrospective Study with Masked Independent Readers. J Nucl Med. 2023. PMID: 37591547. doi:10.2967/jnumed.123.265916

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。